Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma
12/06/2026 17:50
BRIEF-Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma June 12 (Reuters) - Lyell Immunopharma Inc LYEL.O:
LYELL IMMUNOPHARMA PRESENTS UPDATED SAFETY DATA AND TRANSLATIONAL INSIGHTS FOR RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) IN PATIENTS WITH LARGE B-CELL LYMPHOMA AT EUROPEAN HEMATOLOGY ASSOCIATION 2026 CONGRESS
LYELL IMMUNOPHARMA - PINACLE PIVOTAL TRIAL DATA UPDATE EXPECTED H2 2026; BLA SUBMISSION PLANNED H2 2027
LYELL IMMUNOPHARMA - RONDE-CEL TREATED OVER 100 PATIENTS IN 2L AND 3L+ LBCL WITH 97% MANUFACTURING SUCCESS RATE
LYELL IMMUNOPHARMA - NO GRADE 3 OR HIGHER CRS AND LOW RATES OF GRADE 3 OR HIGHER ICANS REPORTED
Source text: ID:nGNX31vqLm
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma